Medikamentöse Therapie bei Patienten mit Leberzirrhose: Aktueller Stand und zukünftige Entwicklungen

Liver cirrhosis is the end stage of chronic liver disease and is associated with high morbidity and mortality, especially in advanced stages. Patients with liver cirrhosis are permanently at risk of a variety of serious complications. Optimal pharmacological management in patients with liver cirrhos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben Khaled, Najib, Allgeier, Julian, Lutz, Teresa, Weber, Sabine, Lange, Christian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2022
Materias:
CME
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247913/
http://dx.doi.org/10.1007/s11377-022-00635-6
_version_ 1784739260632399872
author Ben Khaled, Najib
Allgeier, Julian
Lutz, Teresa
Weber, Sabine
Lange, Christian M.
author_facet Ben Khaled, Najib
Allgeier, Julian
Lutz, Teresa
Weber, Sabine
Lange, Christian M.
author_sort Ben Khaled, Najib
collection PubMed
description Liver cirrhosis is the end stage of chronic liver disease and is associated with high morbidity and mortality, especially in advanced stages. Patients with liver cirrhosis are permanently at risk of a variety of serious complications. Optimal pharmacological management in patients with liver cirrhosis can slow progression of the underlying disease, improve quality of life, avoid hospitalizations by preventing complications, and reduce mortality by treating hepatic decompensation. In this article, we provide an overview of the current status and new developments in pharmacotherapy in patients with liver cirrhosis.
format Online
Article
Text
id pubmed-9247913
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-92479132022-07-01 Medikamentöse Therapie bei Patienten mit Leberzirrhose: Aktueller Stand und zukünftige Entwicklungen Ben Khaled, Najib Allgeier, Julian Lutz, Teresa Weber, Sabine Lange, Christian M. Gastroenterologie CME Liver cirrhosis is the end stage of chronic liver disease and is associated with high morbidity and mortality, especially in advanced stages. Patients with liver cirrhosis are permanently at risk of a variety of serious complications. Optimal pharmacological management in patients with liver cirrhosis can slow progression of the underlying disease, improve quality of life, avoid hospitalizations by preventing complications, and reduce mortality by treating hepatic decompensation. In this article, we provide an overview of the current status and new developments in pharmacotherapy in patients with liver cirrhosis. Springer Medizin 2022-07-01 2022 /pmc/articles/PMC9247913/ http://dx.doi.org/10.1007/s11377-022-00635-6 Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle CME
Ben Khaled, Najib
Allgeier, Julian
Lutz, Teresa
Weber, Sabine
Lange, Christian M.
Medikamentöse Therapie bei Patienten mit Leberzirrhose: Aktueller Stand und zukünftige Entwicklungen
title Medikamentöse Therapie bei Patienten mit Leberzirrhose: Aktueller Stand und zukünftige Entwicklungen
title_full Medikamentöse Therapie bei Patienten mit Leberzirrhose: Aktueller Stand und zukünftige Entwicklungen
title_fullStr Medikamentöse Therapie bei Patienten mit Leberzirrhose: Aktueller Stand und zukünftige Entwicklungen
title_full_unstemmed Medikamentöse Therapie bei Patienten mit Leberzirrhose: Aktueller Stand und zukünftige Entwicklungen
title_short Medikamentöse Therapie bei Patienten mit Leberzirrhose: Aktueller Stand und zukünftige Entwicklungen
title_sort medikamentöse therapie bei patienten mit leberzirrhose: aktueller stand und zukünftige entwicklungen
topic CME
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247913/
http://dx.doi.org/10.1007/s11377-022-00635-6
work_keys_str_mv AT benkhalednajib medikamentosetherapiebeipatientenmitleberzirrhoseaktuellerstandundzukunftigeentwicklungen
AT allgeierjulian medikamentosetherapiebeipatientenmitleberzirrhoseaktuellerstandundzukunftigeentwicklungen
AT lutzteresa medikamentosetherapiebeipatientenmitleberzirrhoseaktuellerstandundzukunftigeentwicklungen
AT webersabine medikamentosetherapiebeipatientenmitleberzirrhoseaktuellerstandundzukunftigeentwicklungen
AT langechristianm medikamentosetherapiebeipatientenmitleberzirrhoseaktuellerstandundzukunftigeentwicklungen

Ejemplares similares